Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity
Key facts
- Who runs it
- University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 17 Oct 2023
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Qsymia and lifestyle management therapy
- Placebo and lifestyle management therapy
- Record updated
- 26 October 2023
- Why it stopped
- The project was not funded
Who can take part
- Age
- 16 years to 22 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Age 16 to less than 22 years at screening
- BMI >/= 25 to < 30 kg/m\^2
- Family history of obesity defined as one biological parent with severe obesity (BMI >/= 35) and/or two biological parents with obesity (BMI >/= 30)
- Age 16 or 17 years old must also have an obesity-related complication/co-morbidity defined as elevated blood pressure (>/= 130 and/or >/= 80 milligrams of mercury [mmHg]) or current use of anti-hypertensive medication, dyslipidemia (triglycerides >/= 150 milligrams/deciliter (mg/dL) and/or HDL cholesterol < 40 mg/dL or current use of cholesterol-lowering medication, diagnosis of obstructive sleep apnea
Who cannot take part
- Current or recent (< 6 months prior to enrollment) use of anti-obesity medication(s) and other weight-altering medication(s) (e.g.,, atypical antipsychotics, attention-deficit hyperactivity disorder [ADHD] stimulant)
- Previous bariatric surgery
- Current or recent (< 6 months prior to enrollment) use of medication(s) to treat insulin resistance
- Recent initiation (< 3 months prior to enrollment) of anti-hypertensive or lipid medication(s)
- Current or recent (< 14 days) use of monoamine oxidase inhibitor
- History of treatment with growth hormone
- Diabetes (1 or 2)
- History of glaucoma
- Known hypersensitivity to sympathomimetic amines
- Eating disorder symptoms within 6 months and/r any past medical diagnosis of eating disorder
- Major psychiatric disorder
- History of suicide attempt
- History of seizures
- Uncontrolled hypertension
- History of structural heart defect
- History of clinically significant arrhythmia
- History of cholelithiasis
- History of nephrolithiasis
- Untreated thyroid disorder
- Alanine transaminase (ALT ) or Aspartate transaminase (AST) >/= 2.5 the upper limit of normal
- Bicarbonate < 18 micromoles per liter (mmol/L)
- Creatinine 1.2 mg/dL
- Creatinine clearance of < 50 microliters per minute [mL/min] (Schwartz formula)
- Tanner stage 1-4
- Patient Health Questionnaire (PHQ) score of >/= 15
- Unstable clinically-diagnosed depression
- Suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last month
- Current pregnancy or breastfeeding
- Plans to become pregnant
- If sexually active, refusal to use 2 forms of birth control
- Tobacco use
- Diagnosed monogenic obesity
- Hyperthyroidism
Where in United States
- University of MinnesotaMinneapolis, United States
About the trial
What the trial wants to find out
This study will test the use of phentermine and topiramate compared with placebo in helping adolescents who are at high risk for developing obesity to lose weight
The 2 groups in the trial
- Medication armTreatment being tested
Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment at 3.75 mg/23 mg orally once in the morning for 14 days, which will then be increased to 7.5 mg/46 mg orally once daily in the morning for the remainder of the trial. Participants who are unable to tolerate the dosing regimen will be maintained at the maximally tolerated dose. To further safeguard the risk/benefit balance we will utilize a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants will be reduced to the lowest-dose level (3.75 mg/23 mg) for 12 weeks. If the BMI remains below 20 kg/m2 at the lowest dose after 12 weeks, active treatment will be fully withdrawn. Participants at the end of the study will be down-titrated gradually with instructions to take the medication every other day for 7 days before stopping treatment altogether.
Treatment: Qsymia and lifestyle management therapy
- Placebo armPlacebo, for comparison
Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment with a placebo (to keep the blind) and be asked to up-titrate the placebo dose after the first 14 days and then maintain the placebo dose for the remainder of the study. Individuals who are unable to tolerate the dosing regimen will have a down-titration protocol (to maintain the blind) as described in the medication arm. Likewise, we will employ a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants would be reduced to the lowest dose level of placebo for 12 weeks. If the BMI remains below 20 kg/m2 after 12 weeks, placebo treatment will be fully withdrawn. Individuals in the placebo arm will also have a placebo-based down-titration with instructions to take the placebo every other day for 7 days before stopping treatment altogether, to maintain the blind.
Treatment: Placebo and lifestyle management therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 October 2023